Oral administration of tepoxalin in the horse: A PK/PD study

Veterinary Journal

Volumn 190, Issue 1, 2011, Pages 143-149

  Giorgi, Mario ^a   Cuniberti, Barbara ^b   Ye, Guisheng ^c   Barbero, Raffaella ^b   Sgorbini, Micaela ^a   Vercelli, Cristina ^b   Corazza, Michele ^a   Re, Giovanni ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c QINGHAI UNIVERSITY   (China)

Author keywords

Horse; Pharmacodynamics; Pharmacokinetics; PK PD; RWJ 20142; Tepoxalin

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; TEPOXALIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DISTRIBUTION VOLUME; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HORSE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHICKENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FASTING; FEMALE; HORSES; PYRAZOLES; RANDOM ALLOCATION;

ANIMALIA; EQUIDAE;

EID: 80053568289     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.09.013     Document Type: Article

References (43)

1. Agnello K.A., Reynolds L.R., Budsberg S.C. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis. American Journal of Veterinary Research 2005, 66:966-972.
2. Anonymous, 2003. Zubrin technical monograph. Schering-Plough Animal Health, Union, NJ 07083-1982.
3. Argentieri D.C., Ritchie D.M., Ferro M.P., Kirchner T., Wachter M.P., Anderson D.W., Rosenthale M.E., Capetola R.J. Tepoxalin: a dual cyclooxygenase/5-lipoxogenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. Journal of Pharmacology and Experimental Therapeutics 1994, 271:1399-1408.
4. Bertolini A., Ottani A., Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacological Research 2001, 44:437-450.
5. Blain H., Boileau C., Lapicque F., Nedelec E., Loeuille D., Guillaume C., Gaucher A., Jeandel C., Netter P., Jouzeau J.Y. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. British Journal of Clinical Pharmacology 2002, 53:255-265.
6. Brideau C., Van Staden C., Chan C.C. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. American Journal of Veterinary Research 2001, 62:1755-1760.
7. Brooks P.M., Day R.O. Nonsteroidal anti-inflammatory drugs: differences and similarities. New England Journal Medicine 1991, 324:1716-1725.
8. Cargile J.L., Burrow J.A., Kim I., Cohen N.D., Merritt A.M. Effect of dietary corn oil supplementation on equine gastric fluid acid, sodium, and prostaglandin E2 content before and during pentagastrin infusion. Journal of Veterinary Internal Medicine 2004, 18:545-549.
9. Caruso M., Zizzadoro C., Crescenzo G., Carofiglio V., Ormas P., Belloli C. Inhibitory effects of tepoxalin on COX1/COX2 and 5-LOX in equine whole blood. Journal of Veterinary Pharmacology and Therapeutics 2009, 32:108.
10. Crooks S.W., Stockley R.A. Leukotriene B4. The International Journal of Biochemistry and Cell Biology 1998, 30:173-178.
11. De Boever S., Neirinckx E., Baert K., De Backer P., Croubels S. Pharmacokinetics of tepoxalin and its active metabolite in broiler chickens. Journal of Veterinary Pharmacology and Therapeutics 2009, 32:97-100.
12. Depré M., Van Hecken A., Verbesselt R., Verpooten G.A., Arnout J., Brunner F., Jurgens A., Pousset V., Chow A., Baldauf C., Vermylen J., De Broe M., De Schepper P.J. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. International Journal of Clinical Pharmacological Research 1996, 16:1-8.
13. Derksen F.J., Olszewski M.A., Robinson N.E., Berney C., Hakala J.E., Matson C.J., Ruth D.T. Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction. American Journal of Veterinary Research 1999, 60:689-693.
14. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2002, Swedish Pharmaceutical Press, Stockholm, Sweden, pp. 114-131.
15. Giorgi M., Ye G., Sgorbini M., Corazza M. Validation of a HPLC-FL method for the determination of tepoxalin and its major metabolite in horse plasma. Journal of Chromatographic Science 2011, 49:79-83.
16. Giraudel J.M., Toutain P.L., Lees P. Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. American Journal of Veterinary Research 2005, 66:700-709.
17. Goldyne M.E. Leukotrienes: clinical significance. Journal of the American Academy of Dermatology 1984, 10:659-668.
18. Goodman L., Torres B., Punke J., Reynolds L., Speas A., Ellis A., Budsberg S. Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. Journal of Veterinary Internal Medicine 2009, 23:56-62.
19. Goodrich L.R., Nixon A.J. Medical treatment of osteoarthritis in the horse - a review. The Veterinary Journal 2006, 171:51-69.
20. Hall J.A., Van Saun R.J., Tornquist S.J., Gradin J.L., Pearson E.G., Wander R.C. Effect of type of dietary polyunsaturated fatty acid supplement (corn oil or fish oil) on immune responses in healthy horses. Journal of Veterinary Internal Medicine 2004, 18:880-886.
21. Higgs G.A., Moncada S. Leukotrienes in disease. Implications for drug development. Drugs 1985, 30:1-5.
22. Homer L.M., Clarke C.R., Weingarten A.J. Effect of dietary fat on oral bioavailability of tepoxalin in dogs. Journal of Veterinary Pharmacology and Therapeutics 2005, 28:287-291.
23. Knight E.V., Kimball J.P., Keenan C.M., Smith I.L., Wong F.A., Barrett D.S., Dempster A.M., Lieuallen W.G., Panigrahi D., Powers W.J., Szot R.J. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundamental and Applied Toxicology 1996, 33:38-48.
24. Lascelles B.D., McFarland J.M., Swann H. Guidelines for safe and effective use of NSAIDs in dogs. Veterinary Therapeutics 2005, 6:237-251.
25. Lees P. Autacoids and anti-inflammatory drugs. Veterinary Pharmacology and Therapeutics 2009, 457-492. Wiley-Blackwell, Ames, IA, USA. J.E. Riviere, J.E. Papich (Eds.).
26. Lees P., Giraudel J., Landoni M.F., Toutain P.L. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:491-502.
27. Lees P., Landoni M.F., Giraudel J., Toutain P.L. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:479-490.
28. Los M., Schenk H., Hexel K., Baeuerle P.A., Droge W., Schulze-Osthoff K. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. The EMBO Journal 1995, 14:3731-3740.
29. Munroe D.G., Lau C.Y. Turning down the heat: new routes to inhibition of inflammatory signaling by prostaglandin H2 synthases. Chemical Biology 1995, 2:343-350.
30. Pollock C.G., Carpenter J.W., Koch D.E., Hunter R.P. Single and multiple-dose pharmacokinetics of tepoxalin and its active metabolite after oral administration to rabbits (Oryctolagus cuniculus). Journal of Veterinary Pharmacology and Therapeutics 2008, 31:171-174.
31. Porter C.J., Charman W.N. Intestinal lymphatic drug transport: an update. Advanced Drug Delivery Reviews 2001, 50:61-80.
32. Rainsford K.D. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice. Agents and Actions 1987, 21:316-319.
33. Rainsford K.D. Leukotrienes in the pathogenesis of NSAID induced gastric and intestinal mucosal damage. Agents and Actions 1993, 39:24-26.
34. Richardson D.W., Loinaz R. An evidence-based approach to selected joint therapies in horses. The Veterinary Clinics of North America Equine Practice 2007, 23:443-460.
35. Santos N.C., Figueira-Coelho J., Martins-Silva J., Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochemical Pharmacology 2003, 65:1035-1041.
36. Stenson W.F., Parker C.W. Leukotrienes. Advances in Internal Medicine 1984, 30:175-199.
37. Tam S.S., Lee D.H., Wang E.Y., Munroe D.G., Lau C.Y. Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities. The Journal of Biological Chemistry 1995, 270:13948-13955.
38. Toutain P.L., Bousquet-Mélou A. Bioavailability and its assessment. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:455-466.
39. Waldman S.A., Vitow C., Osborne B., Gillen L., Argentieri D.C., Wong F.A., Smith I.L., Chow A.T., Misiti J., Bjornsson T.D. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. Journal of Clinical Pharmacology 1996, 36:462-468.
40. Wallace J.L., McCafferty D.M., Carter L., McKnight W., Argentieri D. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy?. Gastroenterology 1993, 105:1630-1636.
41. Warner R.M. Statistical power analysis. Applied Statistics. From Bivariate through Multivariate Techniques 2008, 106-114. Sage Publications, Los Angeles, USA. R.M. Warner (Ed.).
42. Willburger R.E., Wittenberg R.H., Schmidt K., Kleemeyer K.S., Peskar B.A. Antiinflammatory effect of tepoxalin: blood and synovial tissue studied in patients with knee arthrosis. Acta Orthopaedica Scandinavica 1998, 69:295-300.
43. Zubrin (Tepoxalin) European Public assessment Report, European Agency for Evaluation of Medicinal Products, EPARs for authorised medicinal products for veterinary use, Rev. 11, 02/10/08.